Nyxoah to Participate in Upcoming Investor Conferences
September 05 2024 - 3:30PM
Nyxoah to Participate in Upcoming
Investor Conferences
Mont-Saint-Guibert, Belgium – September
5, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext
Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a
medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive
Sleep Apnea (OSA), today announced that the Company will
participate in three upcoming investor conferences in New York
City.
Olivier Taelman, Nyxoah’s Chief Executive
Officer, will deliver corporate updates at the Baird Global
Healthcare Conference on Tuesday, September 10, 2024, at 12:15pm
ET, the H.C. Wainwright 26th Annual Global Investment Conference on
Wednesday, September 11, 2024, at 11:00am ET and the Cantor Global
Healthcare Conference on Wednesday, September 18, 2024 at 1:55pm
ET. Webcasts of the presentations will be available on the Events
section of Nyxoah’s Investor Relations website. The Company will
also be available for 1x1 meetings with institutional investors
attending the events.
Nyxoah’s Investor Presentation can be accessed
on the Shareholder Information section of the Company’s Investor
Relations page.
About Nyxoah
Nyxoah is a medical technology company focused
on the development and commercialization of innovative solutions to
treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the
Genio® system, a patient-centered, leadless and battery-free
hypoglossal neurostimulation therapy for OSA, the world’s most
common sleep disordered breathing condition that is associated with
increased mortality risk and cardiovascular comorbidities. Nyxoah
is driven by the vision that OSA patients should enjoy restful
nights and feel enabled to live their life to its
fullest.
For more information, please see the Company’s
annual report for the financial year 2023 and visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company’s or,
as appropriate, the Company directors’ or managements’ current
expectations regarding the entry into of the loan facility
agreement and the synthetic warrant agreement with the EIB; the use
of proceeds from the loan facility agreement; the Genio® system and
ongoing clinical studies of the Genio® system; the potential
advantages of the Genio® system; Nyxoah’s goals with respect to the
development, regulatory pathway and potential use of the Genio®
system; the utility of clinical data in potentially obtaining FDA
approval of the Genio® system; reporting data from Nyxoah’s DREAM
U.S. pivotal trial; filing for FDA approval; and entrance to the
U.S. market. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that
could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties, assumptions and factors could adversely
affect the outcome and financial effects of the plans and events
described herein. Additionally, these risks and uncertainties
include, but are not limited to, the risks and uncertainties set
forth in the “Risk Factors” section of the Company’s Annual Report
on Form 20-F for the year ended December 31, 2023, filed with the
Securities and Exchange Commission (“SEC”) on March 20, 2024, and
subsequent reports that the Company files with the SEC. A multitude
of factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Contacts:
NyxoahLoïc Moreau, Chief
Financial OfficerIR@nyxoah.com
For
MediaBelgium/FranceBackstage Communication – Gunther De
Backergunther@backstagecom.be
International/GermanyMC Services – Anne
Henneckenyxoah@mc-services.eu
- ENGLISH_Nyxoah to Participate in Upcoming Investor
Conferences
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Sep 2023 to Sep 2024